Standard BioTools Inc. Deferred Tax Liabilities, Net
Standard BioTools Inc. (LAB) had Deferred Tax Liabilities, Net of $943.00 thousand as of 2024-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilities · last filed 2026-03-16
- 2024-12-31: Deferred Tax Liabilities, Net $943.00K.
- 2023-12-31: Deferred Tax Liabilities, Net $706.00K.
- 2022-12-31: Deferred Tax Liabilities, Net $824.00K.
- 2021-12-31: Deferred Tax Liabilities, Net $4.15M.
| Period end | Deferred Tax Liabilities, Net |
|---|---|
| 2024-12-31 | $943.00K 10-K · filed 2026-03-16 |
| 2023-12-31 | $706.00K 10-K · filed 2025-03-11 |
| 2022-12-31 | $824.00K 10-K · filed 2024-03-01 |
| 2021-12-31 | $4.15M 10-K · filed 2023-03-14 |
| 2020-12-31 | $8.46M 10-K · filed 2022-03-08 |
| 2019-12-31 | $11.20M 10-K · filed 2021-02-25 |
| 2018-12-31 | $13.71M 10-K · filed 2020-02-27 |
| 2017-12-31 | $16.09M 10-K · filed 2019-03-18 |
| 2016-12-31 | $19.74M 10-K · filed 2018-03-08 |
| 2015-12-31 | $23.66M 10-K · filed 2017-03-03 |
| 2014-12-31 | $26.12M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |